For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Synlogic Operating Company, Inc.

USPTO Granted Patents = 21

EPO Patents = 5

Forward Citations = 54

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Vincent M Isabella (19 out of 23 patents)

Dean Falb (18 out of 22 patents)

Jonathan W Kotula (18 out of 24 patents)

4. Paul F Miller (18 out of 22 patents)

5. Yves Millet (14 out of 16 patents)

6. Adam B Fisher (9 out of 10 patents)

7. Sarah Rowe (7 out of 8 patents)

8. Suman Machinani (6 out of 8 patents)

9. Saurabh Saha (2 out of 37 patents)

10. Ning Li (2 out of 2 patents)

11. Adam Lawrence (2 out of 2 patents)

12. Per Greisen (2 out of 2 patents)

13. Kristin Adolfsen (2 out of 2 patents)

14. James Spoonamore (2 out of 2 patents)

15. Jay Konieczka (2 out of 2 patents)

21 patents: Sort by Forward Citations

1. 12409195 - Bacteria engineered to reduce hyperphenylalaninemia (2025-09-09),

2. 12171790 - Microorganisms engineered to reduce hyperphenylalaninemia (2024-12-24),

3. 11896627 - Bacteria engineered to treat metabolic diseases (2024-02-13),

4. 11883439 - Bacteria engineered to treat a disease or disorder (2024-01-30),

5. 11879123 - Bacteria for the treatment of disorders (2024-01-23),

6. 11859189 - Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof (2024-01-02),

7. 11845964 - Bacteria engineered to treat diseases associated with hyperammonemia (2023-12-19),

8. 11766463 - Microorganisms engineered to reduce hyperphenylalaninemia (2023-09-26),

9. 11723932 - Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells (2023-08-15),

10. 11685925 - Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier (2023-06-27),

11. 11618894 - Bacteria engineered to reduce hyperphenylalaninemia (2023-04-04),

12. 11471494 - Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells (2022-10-18),

13. 11439673 - Bacteria engineered to treat liver disease (2022-09-13),

14. 11384359 - Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier (2022-07-12),

15. 11291693 - Bacteria engineered to treat metabolic diseases (2022-04-05),

Synlogic is pioneering the development of a novel class of Living Medicines, Synthetic Biotic medicines, based on its proprietary drug discovery and development platform. Synlogic's pipeline includes Synthetic Biotic-based approaches for the treatment of rare genetic diseases, metabolic diseases, and cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

21 Patents

#109 in Cambridge, MA

#903 in Massachusetts

#15,156 in US

#29,052 in the World

Cambridge, MA, United States of America

Synlogic Operating Company, Inc.

Forward Citations = 54

26 inventors:

Vincent M Isabella (19 out of 23 patents)

Dean Falb (18 out of 22 patents)

Jonathan W Kotula (18 out of 24 patents)

4. Paul F Miller (18 out of 22 patents)

5. Yves Millet (14 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…